|
000
| 03074cam 2200349za 4500 |
|---|
| 001 | 9.843655 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20221107152554 |
|---|
| 007 | cr ||||||||||| |
|---|
| 008 | 171003s2017 onc ob f000 0 eng d |
|---|
| 020 | |a978-0-660-09692-6 |
|---|
| 040 | |aCaOODSP|beng |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aMR4-61/2017E-PDF |
|---|
| 245 | 00|aCIHR assessment of the Canadian Guideline for Opioids for Chronic Non-Cancer Pain |h[electronic resource]. |
|---|
| 260 | |aOttawa : |bCanadian Institutes of Health Research, |cc2017. |
|---|
| 300 | |a17 p. |
|---|
| 500 | |aIssued also in French under title: Évaluation des IRSC des Recommandations canadiennes sur l’utilisation des opioïdes pour le traitement de la douleur chronique non cancéreuse. |
|---|
| 500 | |aCover title. |
|---|
| 500 | |aIssued also in HTML format. |
|---|
| 504 | |aIncludes bibliographical references. |
|---|
| 520 | |a“In 2010, recognizing the need to improve safe opioid prescribing practices, a national group of physicians and researchers developed the Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain. This guideline provided recommendations to medical professionals on prescribing opioids safely and effectively. Once the 2010 guideline was published, McMaster University’s Michael G. DeGroote National Pain Centre assumed responsibility for keeping it current by highlighting new evidence. In the years following, the Government of Canada provided funding, through the Canadian Institutes of Health Research and Health Canada, to McMaster University researchers to update the 2010 guideline with new evidence. The revised 2017 Canadian Guideline for Opioids for Chronic Non-Cancer Pain (the 2017 Canadian Guideline) was published in the Canadian Medical Association Journal (CMAJ) on May 8, 2017. Following its release, The Globe and Mail reported that McMaster University did not exclude medical experts who had received income from opioid manufacturers from the 2017 Canadian Guideline’s voting panel. In response to public criticism, the Minister of Health directed CIHR to assess what impact, if any, the potential conflict of interest had on the scientific rigour of the 2017 Canadian Guideline. This review aimed to determine whether the 2017 Canadian Guideline provides unbiased, evidence-based guidance to clinicians on opioid prescribing practices”--p. 3. |
|---|
| 530 | |aIssued also in bilingual print format. |
|---|
| 692 | 07|2gccst|aPrescription drugs |
|---|
| 692 | 07|2gccst|aSafety standards |
|---|
| 692 | 07|2gccst|aReview |
|---|
| 710 | 2 |aCanadian Institutes of Health Research. |
|---|
| 775 | 08|tÉvaluation des IRSC des Recommandations canadiennes sur l’utilisation des opioïdes pour le traitement de la douleur chronique non cancéreuse |w(CaOODSP)9.843656 |
|---|
| 776 | 0#|tCIHR assessment of the Canadian guideline for opioids for chronic non-cancer pain |w(CaOODSP)9.843661 |
|---|
| 856 | 40|qPDF|s800 KB|uhttps://publications.gc.ca/collections/collection_2017/irsc-cihr/MR4-61-2017-eng.pdf |
|---|
| 856 | 4 |qHTML|sN/A|uhttps://cihr-irsc.gc.ca/e/50544.html |
|---|